151 related articles for article (PubMed ID: 10367674)
1. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
3. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.
Puri RK; Leland P; Kreitman RJ; Pastan I
Int J Cancer; 1994 Aug; 58(4):574-81. PubMed ID: 8056454
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
5. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
[TBL] [Abstract][Full Text] [Related]
6. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
[TBL] [Abstract][Full Text] [Related]
7. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
[TBL] [Abstract][Full Text] [Related]
8. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
9. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
[TBL] [Abstract][Full Text] [Related]
10. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
Kunwar S; Pai LH; Pastan I
J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
[TBL] [Abstract][Full Text] [Related]
12. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
13. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
14. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
Debinski W; Obiri NI; Pastan I; Puri RK
J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
16. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
17. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity.
Kreitman RJ; Puri RK; Leland P; Lee B; Pastan I
Biochemistry; 1994 Sep; 33(38):11637-44. PubMed ID: 7918378
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
Kornmann M; Kleeff J; Debinski W; Korc M
Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
[TBL] [Abstract][Full Text] [Related]
19. A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes.
Puri RK; Mehrotra PT; Leland P; Kreitman RJ; Siegel JP; Pastan I
J Immunol; 1994 Apr; 152(7):3693-700. PubMed ID: 8144944
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
Kawakami M; Kawakami K; Puri RK
J Neurooncol; 2003 Oct; 65(1):15-25. PubMed ID: 14649882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
